Sentences with phrase «oncology drugs»
Oncology drugs refer to medications or drugs that are used in the treatment, prevention, or management of cancer. These drugs are specifically designed to target cancer cells and help to slow down or stop their growth, kill them, or prevent their spread to other parts of the body. Full definition
There, he participated in the review of oncology drugs and began to think about law school, not for the first time.
sciencemag.org
In the first of our occasional series, we look at how recent oncology drug advances have had an impact on global skills and recruitment trends.
The company now controls nearly half of the market for insulin products — which are second only to oncology drugs as the fastest - growing category of pharmaceuticals.
A major challenge in oncology drug development remains the identification of predictive biomarkers of efficacy, especially for targeted agents and immuno - therapeutic agents.
Bristol - Myers» main competitor in this field is Merck (mrk), whose immuno - oncology drug Keytruda was approved more than three months before the BMS therapy in 2014.
Given the role of Msi in promoting aggressive disease, the investigators partnered with Robert MacLeod PhD, vice-president of oncology drug discovery at Ionis Pharmaceuticals, to develop next - generation antisense oligonucleotide (ASO) inhibitors against Msi.
GT's lead oncology drug candidate, OXS - 1550 (DT2219) is a novel bispecific scFv recombinant fusion protein - drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload.
During the last three years, iTeos has developed a comprehensive portfolio of immuno - oncology drug candidates and these additional funds will enhance our capability to demonstrate the potential clinical benefits of our products.
Historic success with oncology drug trials and scientific breakthroughs in the West is undeniable.
IDO1 inhibitors are one of the most promising immuno - oncology drugs currently in development.
«The shortage over many oncology drugs at that time was due to large manufacturers having quality problems and having to shut down,» said Valerie Jensen, associated director of the drug shortage staff at the FDA.
«Dr. Hambleton is an accomplished industry executive and a leading oncology drug developer, and we welcome her to the leadership team at IDEAYA,» said Yujiro S. Hata, chief executive officer of IDEAYA.
Beginning in January 2017, IBM employees in the U.S. will be able to use Watson supercomputer technology to help find the most effective oncology drugs and clinical trials for their specific cancers, IBM announced.
In a major cross-border deal, Japanese pharma company Takeda acquired US - based Ariad Pharmaceuticals in order to obtain Ariad's oncology drug pipeline and its scientific capabilities.
ZURICH (Reuters)- Roche's Tecentriq immuno - oncology drug failed a late - stage follow - up trial against advanced bladder cancer, the Swiss drugmaker said on Wednesday, raising questions about whether regulators could scale back their approval of the medicine.
U.S. health regulators on Tuesday granted accelerated approval for Pfizer Inc's immuno - oncology drug Bavencio to treat advanced bladder cancer, marking the second approval in less than two months for the treatment developed along with Germany's Merck KGaA.
Immune oncology drugs use a mechanism to enable the immune system to «uncloak» hidden cancer cells in the body and then attack them.
Sales of immuno - oncology drug Opdivo, the company's most important growth driver, surged 34 percent to $ 1.51 billion, beating analysts» estimates of $ 1.28 billion.
«To me, it's a little bit disconcerting,» says David Johnson, who served on FDA's oncology drugs advisory committee and is deputy director of the Vanderbilt - Ingram Cancer Center in Nashville, Tennessee.
The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer.
Diagnosed with chronic myeloid leukemia in 2007, she benefited from the precision oncology drug Gleevec.
Perhaps the current success of oncology drug approvals in the USA will encourage an increased job market within multinational pharmaceutical companies.
Look out for our upcoming articles in this series as we delve in to more detail about the impact specific oncology drugs, developments and trial locations have had on the recruitment opportunities for Life Science professionals.
Oncology drug development continues to see a high level of activity and funding across the US, despite an uncertain regulatory environment that has left many Big Pharma companies carefully considering their R&D investments and strategies.
The adjusted tally beat consensus expectations of $ 1.00, thanks in part to stronger demand for its standout immuno - oncology drug KEYTRUDA, and management responded by raising its full - year guidance.
Four of the company's immuno - oncology drug trials had to be stopped due to the ethical need to offer the more effective experimental treatment to the other arm of patients receiving standard care.
Michel Detheux, Ph.D., Chief Executive Officer of iTeos Therapeutics, commented: «IDO1 inhibitors are one of the most promising immuno - oncology drugs currently in development.
Since 2004, a wealth of new research has produced a deluge of oncology drugs in development and human trials; more than 900 are being tested today.
Genentech has long been a leader in understanding and advancing the fields of cancer biology, cancer immunology and oncology drug discovery.
These products — largely innovative and pricey specialty medications that include breakthrough Hepatitis C treatments and immuno - oncology drugs — reflect the increased productivity and improved pipelines of pharma's R&D departments in recent years.
Immuno - oncology drugs have proven promising and effective for many patients; but they also don't produce a response in a sizable chunk of the patient pool and may eventually wane in efficacy.
Even though getting a drug to market typically takes ten years, Linear, in its eight years of operation, has already been involved in assisting two oncology drugs to be available for cancer patients.
As a vice president of the $ 38 billion (sales) French drug company Sanofi, Victoria Richon witnessed constant reorganizations that affected her oncology drug development program.
Overall, reports Citigroup drug analyst Andrew Baum, the market for immuno - oncology drugs could be worth $ 35 billion within a decade's time.
• Repare Therapeutics, a Montreal and Boston - based developer of oncology drugs, raised $ 68 million in Series A funding.
The rest comes from its portfolio of hematology and oncology drugs, including Vyxeos for acute myeloid leukemia and Erwinaze for acute lymphoblastic leukemia.
They say they expect next year to start up to 20 patient testing programs of such immuno - oncology drugs.
Initially, Pfizer and Merck KGaA, based in Darmstadt, Germany, plan together to conduct patient testing and seek approval of a Merck experimental drug called MSB0010718C, an immune - oncology drug in a class called anti-PD-L 1 antibodies.
The two companies also will work together on early testing of Pfizer's immuno - oncology drug, an anti-PD-1 antibody.
The company's overall sales jumped 6 %, led by a ramp up in its Oncology drug Keytruda.
In 2011, Yervoy became a breakthrough treatment for metastatic melanoma, and BMS quickly followed that success with another immuno - oncology drug, Opdivo.
The action is good news for patients relying on some oncology drugs, antibiotics, liquid nutrition and anesthetics — all areas that have suffered from shortages in recent years.
«In recent years, there have been a number of oncology drugs that have been touted as potential blockbusters, but most haven't sold as well as expected.
This study utilized 36 well - characterized melanoma cell lines assembled by the MGH Center for Molecular Therapeutics to test all possible combinations of more than 100 oncology drugs, two - thirds of which are currently in clinical use.
BridgeBio has committed $ 30 million and a team of senior business managers to the company, while MD Anderson, through its Institute for Applied Cancer Sciences (IACS), provides intellectual property and an oncology drug development team to advance SHP2 inhibitors toward clinical studies.
He is also a Board member of LiPlasome Pharma ApS, Denmark — an oncology drug delivery company; and Braidlock Limited, a UK medtech company.
Funding will support the clinical development of the Company's lead innovative immuno - oncology drug
Read more... The impact of oncology drug development - part one - 21/03/13 In the first of our occasional series, we look at how recent oncology drug advances have had an impact on global skills and recruitment trends.
Read more... Oncology drug development - spotlight on UK - 02/04/13 Is science investment — and particularly investment in oncology research and development roles - the way to grow the UK economy and push through the recession?